These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Different NT-proBNP circulating levels for different types of cardiac amyloidosis. Perfetto F; Bergesio F; Grifoni E; Fabbri A; Ciuti G; Frusconi S; Angelotti P; Spini V; Cappelli F J Cardiovasc Med (Hagerstown); 2016 Nov; 17(11):810-7. PubMed ID: 26765991 [TBL] [Abstract][Full Text] [Related]
9. Clinical and imaging characteristics of patients with cardiac amyloidosis- a single center observational study. Ingebrigtsen A; Saeed S; Larsen TH; Reikvam H Scand J Clin Lab Invest; 2024 May; 84(3):193-201. PubMed ID: 38709651 [TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition. Biolo A; Ramamurthy S; Connors LH; O'Hara CJ; Meier-Ewert HK; Soo Hoo PT; Sawyer DB; Seldin DC; Sam F Circ Heart Fail; 2008 Nov; 1(4):249-57. PubMed ID: 19808299 [TBL] [Abstract][Full Text] [Related]
11. Biomarkers and Prediction of Prognosis in Transthyretin-Related Cardiac Amyloidosis: Direct Comparison of Two Staging Systems. Cappelli F; Martone R; Gabriele M; Taborchi G; Morini S; Vignini E; Allinovi M; Di Gioia M; Bartolini S; Di Mario C; Perfetto F Can J Cardiol; 2020 Mar; 36(3):424-431. PubMed ID: 32145869 [TBL] [Abstract][Full Text] [Related]
12. Predictors of cardiac involvement and survival in patients with primary systemic light-chain amyloidosis: roles of the clinical, chemical, and 3-D speckle tracking echocardiography parameters. Lei C; Zhu X; Hsi DH; Wang J; Zuo L; Ta S; Yang Q; Xu L; Zhao X; Wang Y; Sun S; Liu L BMC Cardiovasc Disord; 2021 Jan; 21(1):43. PubMed ID: 33478398 [TBL] [Abstract][Full Text] [Related]
13. Echocardiographic and biohumoral characteristics in patients with AL and TTR amyloidosis at diagnosis. Cappelli F; Baldasseroni S; Bergesio F; Perlini S; Salinaro F; Padeletti L; Attanà P; Paoletti Perini A; Moggi Pignone A; Grifoni E; Fabbri A; Marchionni N; Gensini GF; Perfetto F Clin Cardiol; 2015 Feb; 38(2):69-75. PubMed ID: 25645201 [TBL] [Abstract][Full Text] [Related]
15. Cardiopulmonary Exercise Physiology in AL Amyloidosis Patients with Cardiac Involvement and Its Association with Cardiac Imaging Parameters. Briasoulis A; Theodorakakou F; Rempakos A; Petropoulos I; Gavriatopoulou M; Androulakis E; Stamatelopoulos K; Kallianos A; Trakada G; Dimopoulos MA; Kastritis E J Clin Med; 2022 Sep; 11(18):. PubMed ID: 36143084 [TBL] [Abstract][Full Text] [Related]
16. Comparison of usefulness between exercise capacity and echocardiographic indexes of left ventricular function in cardiac amyloidosis. Trikas A; Rallidis L; Hawkins P; Oakley CM; Nihoyannopoulos P Am J Cardiol; 1999 Nov; 84(9):1049-54. PubMed ID: 10569662 [TBL] [Abstract][Full Text] [Related]
17. Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis - Report from the Transthyretin Amyloidosis Outcome Survey (THAOS). Kristen AV; Maurer MS; Rapezzi C; Mundayat R; Suhr OB; Damy T; PLoS One; 2017; 12(4):e0173086. PubMed ID: 28384285 [TBL] [Abstract][Full Text] [Related]
19. Subtype-Specific Interactions and Prognosis in Cardiac Amyloidosis. Sperry BW; Vranian MN; Hachamovitch R; Joshi H; Ikram A; Phelan D; Hanna M J Am Heart Assoc; 2016 Mar; 5(3):e002877. PubMed ID: 27013539 [TBL] [Abstract][Full Text] [Related]
20. Validation of the Boston University staging system in AL amyloidosis. Tomlinson R; Matigian N; Mollee P Amyloid; 2019 Sep; 26(3):125-127. PubMed ID: 31145007 [No Abstract] [Full Text] [Related] [Next] [New Search]